|
| N-Desmethyl Imatinib Basic information |
| N-Desmethyl Imatinib Chemical Properties |
Melting point | 99-101°C | density | 1.268±0.06 g/cm3(Predicted) | storage temp. | -20°C Freezer | solubility | DMF: 16 mg/ml; DMF:PBS (pH 7.2) (1:4): 0.20 mg/ml; DMSO: 14 mg/ml; Ethanol: 0.20 mg/ml | form | A lyophilized solid | pka | 13.28±0.70(Predicted) |
Safety Statements | 24/25 | HS Code | 29339900 |
| N-Desmethyl Imatinib Usage And Synthesis |
Description | N-desmethyl Imatinib is a major active metabolite of imatinib , an anticancer agent that selectively targets tyrosine kinases, including Bcr-ABL, platelet-derived growth factor receptor (PDGFR), and KIT. N-desmethyl Imatinib is formed when imatinib undergoes demethylation by the cytochrome P450 (CYP) isomer CYP3A4. N-desmethyl Imatinib has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib, indicating the majority of the anticancer activity can be attributed to the parent compound. | Chemical Properties | Off-White to Pale-Yellow Solid | Uses | aminoglycoside antibiotic similar to gentamycin, toxic to bacterial, yeast, higher plant and mammalian cells and to protozoans and helminthes | Uses | anti-epileptic | Uses | N-Desmethyl Imatinib (Imatinib EP Impurity C) is a metabolite of Gleevec, a tyrosine kinase inhibitor which is highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It is a COVID19-related research product. | Definition | ChEBI: N-Demethylated piperazine is a member of benzamides. |
| N-Desmethyl Imatinib Preparation Products And Raw materials |
|